作者：
Ribrag, Vincent [1]
;
Lee, Seung Tae [2]
;
Rizzieri, David [3]
;
Dyer, Martin J. S. [4]
;
Fayad, Luis [5]
;
Kurzrock, Razelle [6]
;
Andritsos, Leslie [7]
;
Bouabdallah, Reda [8]
;
Hayat, Amjad [9]
;
Bacon, Larry [10]
;
Jiang, Yu [11]
;
Miah, Kowser ;
Delafont, Bruno ;
Hamid, Oday ;
Anyanwu, Stephanie ;
Martinez, Pablo ;
Hess, Brian
作者单位：
Univ Hosp Galway, Dept Haematol, Galway, Ireland
[1]
Inst Gustave Roussy, Dept Hematol, Early Drug Dev, Villejuif, France
[2]
Univ New Mexico, Div Hematol Oncol, Albuquerque, NM 87131 USA
[3]
Univ Leicester, Ernest & Helen Scott Hematol Res Inst, Leicester, Leics, England
[4]
AstraZeneca, Gaithersburg, MD USA
[5]
MUSC Hlth Hollings Canc Ctr, Div Hematol & Oncol, Charleston, SC USA
[6]
St James Hosp, Dept Haematol, Dublin, Ireland
[7]
Univ Maryland, Dept Med, Baltimore, MD 21201 USA
[8]
Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA
[9]
MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[10]
Inst Paoli Calmettes Unicanc, Dept Hematol, Paris, France
[11]
发布时间
2021-09-07
换一批
